# A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

> **NCT01745094** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 223 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** mirabegron
- **DRUG:** solifenacin

## Key facts

- **NCT ID:** NCT01745094
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-01
- **Primary completion:** 2013-07-23
- **Final completion:** 2013-07-23
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2018-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01745094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01745094, "A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01745094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*